Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JQTJ | ISIN: US22663K1079 | Ticker-Symbol: 6Z4
Tradegate
04.07.25 | 12:09
25,400 Euro
-0,78 % -0,200
1-Jahres-Chart
CRINETICS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CRINETICS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
25,00025,40013:02
25,20025,60012:37

Aktuelle News zur CRINETICS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCrinetics-Aktienrating von JMP vor wichtigen Daten bei "Market Outperform" bestätigt2
CRINETICS PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiCrinetics stock rating reiterated at Market Outperform by JMP ahead of key data2
MoCrinetics Pharmaceuticals, Inc.: Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline1
27.06.H.C. Wainwright bekräftigt Kaufempfehlung für Crinetics-Aktie mit Kursziel von 81 US-Dollar1
27.06.H.C. Wainwright reiterates buy rating on Crinetics stock at $81 target1
26.06.Crinetics Pharmaceuticals, Inc. - 8-K, Current Report2
12.06.Crinetics Pharmaceuticals, Inc. - 8-K, Current Report1
10.06.Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)104SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified...
► Artikel lesen
30.05.H.C. Wainwright maintains Crinetics stock Buy rating, $81 target14
15.05.Crinetics Pharmaceuticals, Inc.: Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 20252
08.05.Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update86Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date CALM-CAH Phase 3 Study of Atumelnant...
► Artikel lesen
11.04.Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 20256
10.04.Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)130SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified...
► Artikel lesen
04.04.Crinetics Pharmaceuticals, Inc. - 8-K, Current Report1
27.03.Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly104SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application...
► Artikel lesen
26.03.JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics' Atumelnant Data4
25.03.Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology2
10.03.Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)138SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified...
► Artikel lesen
03.03.Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2024 Earnings Call Transcript1
28.02.Cantor Fitzgerald lifts Crinetics stock target to $1006
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1